A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, single-dose, phase 1 study, to assess the effect of mild
and moderate hepatic impairment on the pharmacokinetics of cenerimod (ACT-334441).